GlobeNewswire Clinical StudiesOriginal article
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Phase 2positiverexaceractPositive
AI Analysis
Summary
Gain Therapeutics reported positive Phase 1b open-label extension data for rexaceract in Parkinson's disease, demonstrating motor score stability and no disease progression through 12 months of daily oral dosing in 12 evaluable participants.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Patients
12
Outcome Details
MDS-UPDRS motor scores demonstrated stability to baseline with no disease progression among 12 evaluable participants at 12 months
Importance:6/10
Sentiment:
0.75
Phase 1bopen-label extensionParkinson's diseasedisease-modifyingpositive datamotor scores
Read the original article
Published by GlobeNewswire Clinical Studies on October 1, 2026 1:28 PM